EUVIMEDEUVIMED entdecken
Crossref

Immunity testing against COVID-19 from blood by an IoT-enabled and AI-controlled multiplexed microfluidic platform

Nabil H Bhuiyan, Joon S Shim

Biosensors and Bioelectronics · 2024-01 · 244 · 115791

DOI: 10.1016/j.bios.2023.115791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biosensors and Bioelectronics, 2024-01. Verfasst von Nabil H Bhuiyan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Bio-IT Convergence Laboratory, Dept. of Electronic Convergence Engineering, KwangWoon University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: COVID-19, Biosensing Techniques. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Developing herd immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pivotal for changing the course of the coronavirus disease 2019 (COVID-19) pandemic. However, the uncertainty of vaccine-induced immunity development and inequitable distribution of vaccines hinders the global vaccination effort. Therefore, routine serodiagnosis and ensuring effective vaccination on a time-to-time basis are essential for developing sustainable immunity against SARS-CoV-2. Herein, an AI-driven multiplexed point-of-care testing (POCT) platform capable of utilizing a microfluidic lab-on-a-chip (LOC) device has been proposed for analyzing bodily fluid response against SARS-CoV-2. The developed platform has been successfully utilized for the quantification of SARS-CoV-2 S-protein, N-protein, IgM, and IgG from human blood samples with limits of detection (LODs) as low as 0.01, 0.02, 0.69, and 0.61 ng/mL respectively. Finally, a data-receptive web-based dashboard system has been developed and demonstrated to provide real-time, territory-specific analysis of herd immunity progress from the test results. Thus, the proposed platform could be an imperative tool for healthcare authorities to analyze and restrain ongoing COVID-19 outbreaks or similar pandemics in the future by ensuring effective immunization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Biosensing TechniquesHumansSARS-CoV-2MicrofluidicsArtificial IntelligenceAntibodies, Viral

Stichwörter der Autor:innen

Artificial intelligence (AI)Internet-of-things (IoT)MicrofluidicsMultiplexSARS-CoV-2Vaccine

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Bio-IT Convergence Laboratory, Dept. of Electronic Convergence Engineering, KwangWoon University, Seoul, Republic of Korea.
  • Bio-IT Convergence Laboratory, Dept. of Electronic Convergence Engineering, KwangWoon University, Seoul, Republic of Korea. Electronic address: shim@kw.ac.kr.

Zitieren

APA

Bhuiyan, N. H., & Shim, J. S. (2024). Immunity testing against COVID-19 from blood by an IoT-enabled and AI-controlled multiplexed microfluidic platform. Biosensors and Bioelectronics, 244, 115791. https://doi.org/10.1016/j.bios.2023.115791

Vancouver

Bhuiyan NH, Shim JS. Immunity testing against COVID-19 from blood by an IoT-enabled and AI-controlled multiplexed microfluidic platform. Biosensors and Bioelectronics. 2024;244:115791. doi:10.1016/j.bios.2023.115791

BibTeX
@article{Bhuiyan2024,
  author = {Bhuiyan, Nabil H and Shim, Joon S},
  title = {Immunity testing against COVID-19 from blood by an IoT-enabled and AI-controlled multiplexed microfluidic platform},
  journal = {Biosensors and Bioelectronics},
  year = {2024},
  volume = {244},
  pages = {115791},
  doi = {10.1016/j.bios.2023.115791}
}
Kostenlos starten →